Halotestin vs LGD-4033
Well Studied vs Moderate Research
avoid Mechanism-based · 64% Both Halotestin and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Halotestin LGD-4033
Weight 336.44 Da 338.25 Da
Half-life ~9.5 hours ~24-36 hours
Type 9-fluoro-11-beta-hydroxy-17-alpha-methyltestosterone (C20H29FO3) Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Halotestin
01 Dramatic increase in strength and power output without water retention
02 Pronounced increase in aggression and competitive drive
03 Does not aromatize to estrogen, producing a hard and dry appearance
04 Enhances red blood cell production and oxygen-carrying capacity
05 Rapid onset of effects, typically noticeable within days
06 Uniquely suited for pre-competition or pre-meet peaking protocols
07 Short cycle duration limits cumulative exposure
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Side Effects
Halotestin
Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)
Pronounced aggression and irritability
HDL cholesterol suppression and LDL elevation
Elevated blood pressure
Headaches (frequently reported, may be related to blood pressure changes)
Suppression of endogenous testosterone production
Oily skin and acne
Decreased appetite (potentially related to liver stress)
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Known or suspected prostate cancer
Breast cancer in males
Pregnancy (Category X - causes fetal harm)
Active liver disease or existing hepatic impairment
Severe cardiovascular disease or uncontrolled hypertension
Hypercalcemia
Nephrosis or nephrotic phase of nephritis
History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use
Hypersensitivity to fluoxymesterone or any formulation component
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Halotestin LGD-4033
Status Well Studied Moderate Research
References 5 studies 5 studies
Latest October 2023 2018
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.